Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Skip to main content

Tumor necrosis factor alpha (TNF alpha) is a cytokine with many biological functions of relevance to inflammatory disease. Although only one of several inflammatory mediators produced in abundance in rheumatoid arthritis (RA), experimental data suggest that it is in a dominant position within a cytokine hierarchy and is therefore a prime target for directed immunotherapy in this disease. We have targeted TNF alpha in vivo using a chimerised monoclonal anti-TNF alpha antibody and have now demonstrated beneficial responses to treatment in three different clinical trials. The results confirm that TNF alpha is of central importance in the inflammatory process in RA and define a new treatment strategy in this disease.

Original publication




Journal article


International journal of immunopharmacology

Publication Date





141 - 145


Kennedy Institute of Rheumatology, London, U.K.


Animals, Humans, Mice, Arthritis, Rheumatoid, Tumor Necrosis Factor-alpha, Acute-Phase Proteins, Recombinant Fusion Proteins, Antibodies, Monoclonal, Cytokines, Treatment Outcome, Female, Male, Clinical Trials as Topic